Cisatracurium Besylate and Pamidronate Intravenous Infusion

• Generic Name: cisatracurium
• Dosage Forms: n.a.
• Other Brand Names: Nimbex

Production of skeletal muscle relaxation during surgery after general anesthesia has been induced.

Facilitation of endotracheal intubation; however, a neuromuscular blocking agent with a rapid onset of action (e.g., succinylcholine, rocuronium) generally preferred in emergency situations when rapid intubation is required. Cisatracurium is not recommended for rapid sequence intubation because of its intermediate onset of action.

Also has been used to facilitate mechanical ventilation in the ICU. Has been given as a continuous IV infusion for up to 6 days in this setting. Whenever neuromuscular blocking agents are used in the ICU, consider benefits versus risks of such therapy and assess patients frequently to determine need for continued paralysis. (See Intensive Care Setting under Cautions.)

Compared with other neuromuscular blocking agents, cisatracurium has an intermediate onset and duration of action; exhibits minimal, if any, cardiovascular effects; and causes less histamine release than atracurium. Because elimination is not dependent on renal or hepatic pathways, may be particularly useful in patients with hepatic or renal dysfunction.

• Generic Name: pamidronate
• Dosage Forms: injection, solution
• Other Brand Names: Aredia

Pamidronate is a bisphosphonate (bis FOS fo nayt) medicine that alters bone formation and breakdown in the body. This can slow bone loss and may help prevent bone fractures.

Pamidronate is used to treat Paget's disease of bone. Pamidronate is also used to treat high blood levels of calcium caused by cancer (also called hypercalcemia of malignancy).

Pamidronate is also used to treat bone damage caused by certain types of cancer such as breast cancer or bone marrow cancer. Pamidronate does not treat the cancer itself.

Pamidronate may also be used for purposes not listed in this medication guide.